In last trading session, Regulus Therapeutics Inc (NASDAQ:RGLS) saw 1.05 million shares changing hands with its beta currently measuring 0.36. Company’s recent per share price level of $7.84 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $542.80M. That closing price of RGLS’s stock is at a discount of -4.59% from its 52-week high price of $8.20 and is indicating a premium of 89.41% from its 52-week low price of $0.83. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.79 million shares which gives us an average trading volume of 1.89 million if we extend that period to 3-months.
For Regulus Therapeutics Inc (RGLS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.67. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.18 in the current quarter.
Regulus Therapeutics Inc (NASDAQ:RGLS) trade information
Regulus Therapeutics Inc’s shares saw a change of 396.20% in year-to-date performance and have moved -0.13% in past 5-day. Regulus Therapeutics Inc (NASDAQ:RGLS) showed a performance of 310.47% in past 30-days. Number of shares sold short was 2.71 million shares which calculate 1.08 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a fall of -12.0% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 7. It follows that stock’s current price would jump 10.71% in reaching the projected high whereas dropping to the targeted low would mean a gain of 10.71% for stock’s current value.
Regulus Therapeutics Inc (RGLS) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 40.21% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -10.57% while estimates for its earnings growth in next 5 years are of 11.89%.
Regulus Therapeutics Inc (NASDAQ:RGLS)’s Major holders
Insiders are in possession of 2.69% of company’s total shares while institution are holding 83.87 percent of that, with stock having share float percentage of 86.19%. Investors also watch the number of corporate investors in a company very closely, which is 83.87% institutions for Regulus Therapeutics Inc that are currently holding shares of the company. FEDERATED HERMES, INC. is the top institutional holder at RGLS for having 12.85 million shares of worth $22.94 million. And as of 2024-06-30, it was holding 19.9374 of the company’s outstanding shares.
The second largest institutional holder is RA CAPITAL MANAGEMENT, L.P., which was holding about 6.25 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.6952 of outstanding shares, having a total worth of $11.16 million.
On the other hand, Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund and Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025 , the former fund manager was holding 7.88 shares of worth $61.79 million or 11.38% of the total outstanding shares. The later fund manager was in possession of 7.42 shares on Jan 31, 2025 , making its stake of worth around $58.15 million in the company or a holder of 10.71% of company’s stock.
